LG Chem, Ltd.
http://www.lgchem.com/global/main
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From LG Chem, Ltd.
Vir Hopes To Take On Gilead’s Hepcludex After Positive Early Hepatitis D Results
The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
Ionis Could Be A Factor In MASH With Positive Phase II Data
Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- AVEO Pharmaceuticals, Inc.
- LG LI
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice